Efficiency and safety of 12 antimicrobial drug regimens against multidrug-resistant gram-negative bacterial infections: a network meta-analysis_Chinese Journal of Evidence-Based Medicine

Authors：

HUANG Benrun ¹ , OUYANG Ronglan ² , GUO Xiaodan ¹ ,  OUYANG Hua ³ , LI Shuang ⁴ ,  DAI Li ¹

1. Department of Pharmacy, The 9l0th Hospital of the Joint Logistics Support Force of the People's Liberation Army of China, Quanzhou 362000, P. R. China;
2. Department of Burn and Plastic Surgery, The 9l0th Hospital of the Joint Logistics Support Force of the People's Liberation Army of China, Quanzhou 362000, P. R. China;
3. Department of Pharmacy, Zhongshan Hospital Affiliated to Xiamen University, Xiamen 361004, P. R. China;
4. Department of Respiratory and Critical Care Medicine, Shandong Second Medical University Affiliated Qingdao Eighth People’s Hospital, Qingdao 266121, P. R. China;

Corresponding author：

OUYANG Hua, Email: oyh820@126.com; DAI Li, Email: dailyjia@163.com

Keywords：

Multidrug-resistant gram-negative infections; Carbapenems; Network meta-analysis; Randomised controlled trials; Cohort study

DOI：

10.7507/1672-2531.202405139

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To systematically review the efficacy and safety of 12 antimicrobial drug regimens for the treatment of multidrug-resistant Gram-negative bacterial (MDR-GNB) infections. Methods The PubMed, Cochrane Library, Web of Science, ClinicalTrials, CNKI, WanFang Data, and Chinese Medical Journal Full-text Database were electronically searched to collect studies related to objectives form inception to February 2023. Two researchers independently screened the literature, extracted data, and assessed the risk of bias in the included studies. Stata software was then used to perform a network meta-analysis. Results A total of 64 articles were included. The network meta-analysis results indicated that combination regimens based on carbapenems, β-lactam/combination agents, or tigecycline showed higher clinical antibacterial effectiveness and bacterial clearance rates for resistant bacterial infections. Among all regimens, tigecycline + β-lactam/combination agent, polymyxin + β-lactam/combination agent, and triple-therapy regimens exhibited superior antibacterial effects. Moreover, most combination regimens containing carbapenems had lower mortality risks, with carbapenems combined with aminoglycosides, β-lactam/combination agents, or polymyxins ranking high in clinical or bacteriological efficacy. Conclusion Current evidence suggests that combination regimens based on β-lactam/combination agents, carbapenems, and tigecycline may be beneficial for improving the clinical and bacteriological efficacy of treating resistant bacterial infections. Due to the limited quantity and quality of the included studies, more high-quality studies are needed to verify the above conclusion.

1.	Zheng JY, Huang SS, Huang SH, et al. Colistin for pneumonia involving multidrug-resistant Acinetobacter calcoaceticus-Acinetobacter baumannii complex. J Microbiol Immunol Infect, 2020, 53(6): 854-865.
2.	Lodise TP, Bassetti M, Ferrer R, et al. All-cause mortality rates in adults with carbapenem-resistant Gram-negative bacterial infections: a comprehensive review of pathogen-focused, prospective, randomized, interventional clinical studies. Expert Rev Anti Infect Ther, 2022, 20(5): 707-719.
3.	Bassetti M, Echols R, Matsunaga Y, et al. Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial. Lancet Infect Dis, 2021, 21(2): 226-240.
4.	Kengkla K, Kongpakwattana K, Saokaew S, et al. Comparative efficacy and safety of treatment options for MDR and XDR Acinetobacter baumannii infections: a systematic review and network meta-analysis. J Antimicrob Chemother, 2018, 73(1): 22-32.
5.	Hutton B, Salanti G, Caldwell DM, et al. The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann Intern Med, 2015, 162(11): 777-784.
6.	Paul M, Daikos GL, Durante-Mangoni E, et al. Colistin alone versus colistin plus meropenem for treatment of severe infections caused by carbapenem-resistant Gram-negative bacteria: an open-label, randomised controlled trial. Lancet Infect Dis, 2018, 18(4): 391-400.
7.	Khalili H, Shojaei L, Mohammadi M, et al. Meropenem/colistin versus meropenem/ampicillin-sulbactam in the treatment of carbapenem-resistant pneumonia. J Comp Eff Res, 2018, 7(9): 901-911.
8.	Wunderink RG, Matsunaga Y, Ariyasu M, et al. Cefiderocol versus high-dose, extended-infusion meropenem for the treatment of Gram-negative nosocomial pneumonia (APEKS-NP): a randomised, double-blind, phase 3, non-inferiority trial. Lancet Infect Dis, 2021, 21(2): 213-225.
9.	Sirijatuphat R, Thamlikitkul V. Preliminary study of colistin versus colistin plus fosfomycin for treatment of carbapenem-resistant Acinetobacter baumannii infections. Antimicrob Agents Chemother, 2014, 58(9): 5598-5601.
10.	Durante-Mangoni E, Signoriello G, Andini R, et al. Colistin and rifampicin compared with colistin alone for the treatment of serious infections due to extensively drug-resistant Acinetobacter baumannii: a multicenter, randomized clinical trial. Clin Infect Dis, 2013, 57(3): 349-358.
11.	Aydemir H, Akduman D, Piskin N, et al. Colistin vs. the combination of colistin and rifampicin for the treatment of carbapenem-resistant Acinetobacter baumannii ventilator-associated pneumonia. Epidemiol Infect, 2013, 141(6): 1214-1222.
12.	Cisneros JM, Rosso-Fernández CM, Roca-Oporto C, et al. Colistin versus meropenem in the empirical treatment of ventilator-associated pneumonia (Magic Bullet study): an investigator-driven, open-label, randomized, noninferiority controlled trial. Crit Care, 2019, 23(1): 383.
13.	Amat T, Gutiérrez-Pizarraya A, Machuca I, et al. The combined use of tigecycline with high-dose colistin might not be associated with higher survival in critically ill patients with bacteraemia due to carbapenem-resistant Acinetobacter baumannii. Clin Microbiol Infect, 2018, 24(6): 630-634.
14.	Batirel A, Balkan II, Karabay O, et al. Comparison of colistin-carbapenem, colistin-sulbactam, and colistin plus other antibacterial agents for the treatment of extremely drug-resistant Acinetobacter baumannii bloodstream infections. Eur J Clin Microbiol Infect Dis, 2014, 33(8): 1311-1322.
15.	Katip W, Uitrakul S, Oberdorfer P. The effectiveness and nephrotoxicity of loading dose colistin combined with or without meropenem for the treatment of carbapenem-resistant A. baumannii. Int J Infect Dis, 2020, 97: 391-395.
16.	Falagas ME, Rafailidis PI, Ioannidou E, et al. Colistin therapy for microbiologically documented multidrug-resistant Gram-negative bacterial infections: a retrospective cohort study of 258 patients. Int J Antimicrob Agents, 2010, 35(2): 194-199.
17.	Yilmaz GR, Guven T, Guner R, et al. Colistin alone or combined with sulbactam or carbapenem against A. baumannii in ventilator-associated pneumonia. J Infect Dev Ctries, 2015, 9(5): 476-487.
18.	Michalopoulos A, Fotakis D, Virtzili S, et al. Aerosolized colistin as adjunctive treatment of ventilator-associated pneumonia due to multidrug-resistant Gram-negative bacteria: a prospective study. Respir Med, 2008, 102(3): 407-412.
19.	Abdelsalam MFA, Abdalla MS, El-Abhar HSE. Prospective, comparative clinical study between high-dose colistin monotherapy and colistin-meropenem combination therapy for treatment of hospital-acquired pneumonia and ventilator-associated pneumonia caused by multidrug-resistant Klebsiella pneumoniae. J Glob Antimicrob Resist, 2018, 15: 127-135.
20.	Paul M, Bishara J, Levcovich A, et al. Effectiveness and safety of colistin: prospective comparative cohort study. J Antimicrob Chemother, 2010, 65(5): 1019-1027.
21.	Shields RK, Nguyen MH, Chen L, et al. Ceftazidime-avibactam is superior to other treatment regimens against carbapenem-resistant Klebsiella pneumoniae bacteremia. Antimicrob Agents Chemother, 2017, 61(8): e00883-817.
22.	Rigatto MH, Vieira FJ, Antochevis LC, et al. Polymyxin B in combination with antimicrobials lacking in vitro activity versus polymyxin b in monotherapy in critically Ill patients with acinetobacter baumannii or pseudomonas aeruginosa infections. Antimicrob Agents Chemother, 2015, 59(10): 6575-6580.
23.	Crusio R, Rao S, Changawala N, et al. Epidemiology and outcome of infections with carbapenem-resistant Gram-negative bacteria treated with polymyxin B-based combination therapy. Scand J Infect Dis, 2014, 46(1): 1-8.
24.	López-Cortés LE, Cisneros JM, Fernández-Cuenca F, et al. Monotherapy versus combination therapy for sepsis due to multidrug-resistant Acinetobacter baumannii: analysis of a multicentre prospective cohort. J Antimicrob Chemother, 2014, 69(11): 3119-3126.
25.	Falagas ME, Rafailidis PI, Kasiakou SK, et al. Effectiveness and nephrotoxicity of colistin monotherapy vs. colistin-meropenem combination therapy for multidrug-resistant Gram-negative bacterial infections. Clin Microbiol Infect, 2006, 12(12): 1227-1230.
26.	Petrosillo N, Giannella M, Antonelli M, et al. Clinical experience of colistin-glycopeptide combination in critically ill patients infected with Gram-negative bacteria. Antimicrob Agents Chemother, 2014, 58(2): 851-858.
27.	Katip W, Oberdorfer P. Clinical efficacy and nephrotoxicity of colistin alone versus colistin plus vancomycin in critically Ill patients infected with Carbapenem-resistant Acinetobacter baumannii: a propensity score-matched analysis. Pharmaceutics, 2021, 13(2): 162.
28.	Park SY, Si HJ, Eom JS, et al. Survival of carbapenem-resistant Acinetobacter baumannii bacteremia: colistin monotherapy versus colistin plus meropenem. J Int Med Res, 2019, 47(12): 5977-5985.
29.	Shi H, Lee JS, Park SY, et al. Colistin plus carbapenem versus colistin monotherapy in the treatment of Carbapenem-resistant Acinetobacter baumannii pneumonia. Infect Drug Resist, 2019, 12: 3925-3934.
30.	Katip W, Uitrakul S, Oberdorfer P. A comparison of colistin versus colistin plus meropenem for the treatment of Carbapenem-resistant Acinetobacter baumannii in critically Ill patients: a propensity score-matched analysis. Antibiotics (Basel), 2020, 9(10): 647.
31.	Seok H, Choi WS, Lee S, et al. What is the optimal antibiotic treatment strategy for carbapenem-resistant Acinetobacter baumannii (CRAB). A multicentre study in Korea. J Glob Antimicrob Resist, 2021, 24: 429-439.
32.	Qureshi ZA, Paterson DL, Potoski BA, et al. Treatment outcome of bacteremia due to KPC-producing Klebsiella pneumoniae: superiority of combination antimicrobial regimens. Antimicrob Agents Chemother, 2012, 56(4): 2108-2113.
33.	Simsek F, Gedik H, Yildirmak MT, et al. Colistin against colistin-only-susceptible Acinetobacter baumannii-related infections: monotherapy or combination therapy. Indian J Med Microbiol, 2012, 30(4): 448-452.
34.	Lee CM, Lim HK, Liu CP, et al. Treatment of pan-drug resistant Acinetobacter baumannii. Scand J Infect Dis, 2005, 37(3): 195-199.
35.	Chan JD, Graves JA, Dellit TH. Antimicrobial treatment and clinical outcomes of carbapenem-resistant Acinetobacter baumannii ventilator-associated pneumonia. J Intensive Care Med, 2010, 25(6): 343-348.
36.	Tasbakan MS, Pullukcu H, Sipahi OR, et al. Is tigecyclin a good choice in the treatment of multidrug-resistant Acinetobacter baumannii pneumonia. J Chemother, 2011, 23(6): 345-349.
37.	Garnacho-Montero J, Amaya-Villar R, Gutiérrez-Pizarraya A, et al. Clinical efficacy and safety of the combination of colistin plus vancomycin for the treatment of severe infections caused by carbapenem-resistant Acinetobacter baumannii. Chemotherapy, 2013, 59(3): 225-231.
38.	Jean SS, Hsieh TC, Hsu CW, et al. Comparison of the clinical efficacy between tigecycline plus extended-infusion imipenem and sulbactam plus imipenem against ventilator-associated pneumonia with pneumonic extensively drug-resistant Acinetobacter baumannii bacteremia, and correlation of clinical efficacy with in vitro synergy tests. J Microbiol Immunol Infect, 2016, 49(6): 924-933.
39.	Cheng A, Chuang YC, Sun HY, et al. Excess mortality associated with colistin-tigecycline compared with colistin-carbapenem combination therapy for extensively drug-resistant Acinetobacter baumannii bacteremia: a multicenter prospective observational study. Crit Care Med, 2015, 43(6): 1194-1204.
40.	Khawcharoenporn T, Pruetpongpun N, Tiamsak P, et al. Colistin-based treatment for extensively drug-resistant Acinetobacter baumannii pneumonia. Int J Antimicrob Agents, 2014, 43(4): 378-382.
41.	Kalin G, Alp E, Akin A, et al. Comparison of colistin and colistin/sulbactam for the treatment of multidrug resistant Acinetobacter baumannii ventilator-associated pneumonia. Infection, 2014, 42(1): 37-42.
42.	张银维, 周华, 蔡洪流, 等. 鲍曼不动杆菌血流感染临床特征和死亡危险因素分析. 中华内科杂志, 2016, 55(2): 121-126.
43.	贺黉裕, 吴雪飞, 居旻杰, 等. 多黏菌素B对脓毒症合并泛耐药革兰阴性菌感染患者的疗效. 中国临床医学, 2021, 28(2): 241-247.
44.	邱莹玉. 硫酸多粘菌素B与美罗培南联用对泛耐药鲍曼不动杆菌菌血症患者的临床疗效与安全性评价. 抗感染药学, 2019, 16(3): 427-429.
45.	徐玲. 硫酸多粘菌素B与美罗培南联用对泛耐药鲍曼不动杆菌菌血症患者的临床疗效与安全性评价. 抗感染药学, 2019, 16(10): 1743-1745.
46.	赵军喜. 美罗培南加左氧氟沙星静滴联合阿米卡星雾化吸入治疗肺部泛耐药铜绿假单胞菌感染. 航空航天医学杂志, 2013, 24(4): 474-475.
47.	汪卫立, 丁伟琪, 黄建东, 等. 美罗培南联合硫酸多粘菌素B对泛耐药鲍曼不动杆菌菌血症患者效果观察及对PCT和CRP影响. 全科医学临床与教育, 2020, 18(3): 212-214.
48.	王玺, 胡艳, 阙呈立, 等. 碳青霉烯类抗生素延长输注联合舒巴坦对广泛耐药鲍曼不动杆菌呼吸机相关性肺炎的疗效. 中华医学杂志, 2017, 97(38): 2996-3000.
49.	王龙梅, 高志凌, 尹硕淼, 等. 头孢哌酮/舒巴坦联合替加环素对耐碳青霉烯类鲍曼不动杆菌感染患者APACHEⅡ评分及炎症反应的影响. 现代生物医学进展, 2022, 22(19): 3776-3779.
50.	詹晓娟, 秦中辉. 替加环素联合头孢哌酮舒巴坦钠在耐碳青霉烯类耐药鲍曼不动杆菌肺炎患者抗感染中的疗效分析. 中国医学工程, 2022, 30(6): 75-78.
51.	李瑞霞. 替加环素与头孢哌酮-舒巴坦联用对耐碳青霉烯类鲍曼不动杆菌肺炎患者的疗效及其对炎症因子的影响. 抗感染药学, 2017, 14(7): 1372-1374.
52.	杨建辉, 孟园园. 替加环素联合注射用头孢哌酮舒巴坦钠治疗碳青霉烯类耐药鲍曼不动杆菌所致医院获得性肺炎患者的效果. 河南医学研究, 2021, 30(10): 1825-1827.
53.	Zheng JY, Huang SS, Huang SH, et al. Colistin for pneumonia involving multidrug-resistant Acinetobacter calcoaceticus-Acinetobacter baumannii complex. J Microbiol Immunol Infect, 2020, 53(6): 854-865.
54.	Guner R, Hasanoglu I, Keske S, et al. Outcomes in patients infected with carbapenem-resistant Acinetobacter baumannii and treated with tigecycline alone or in combination therapy. Infection, 2011, 39(6): 515-518.
55.	Ku K, Pogue JM, Moshos J, et al. Retrospective evaluation of colistin versus tigecycline for the treatment of Acinetobacter baumannii and/or carbapenem-resistant Enterobacteriaceae infections. Am J Infect Control, 2012, 40(10): 983-987.
56.	Tsioutis C, Kritsotakis EI, Karageorgos SA, et al. Clinical epidemiology, treatment and prognostic factors of extensively drug-resistant Acinetobacter baumannii ventilator-associated pneumonia in critically ill patients. Int J Antimicrob Agents, 2016, 48(5): 492-497.
57.	Kofteridis DP, Andrianaki AM, Maraki S, et al. Treatment pattern, prognostic factors, and outcome in patients with infection due to pan-drug-resistant gram-negative bacteria. Eur J Clin Microbiol Infect Dis, 2020, 39(5): 965-970.
58.	Ghafur A, Devarajan V, Raja T, et al. Monotherapy versus combination therapy against carbapenem-resistant Gram-negative bacteria: a retrospective observational study. Indian J Cancer, 2016, 53(4): 592-594.
59.	Zaidi ST, Al Omran S, Al Aithan AS, et al. Efficacy and safety of low-dose colistin in the treatment for infections caused by multidrug-resistant gram-negative bacteria. J Clin Pharm Ther, 2014, 39(3): 272-276.
60.	Wagenlehner FME, Cloutier DJ, Komirenko AS, et al. Once-daily plazomicin for complicated urinary tract infections. N Engl J Med, 2019, 380(8): 729-740.
61.	Qu J, Feng C, Li H, et al. Antibiotic strategies and clinical outcomes for patients with carbapenem-resistant Gram-negative bacterial bloodstream infection. Int J Antimicrob Agents, 2021, 57(3): 106284.
62.	Makris D, Petinaki E, Tsolaki V, et al. Colistin versus colistin combined with ampicillin-sulbactam for multiresistant Acinetobacter baumannii ventilator-associated pneumonia treatment: an open-label prospective study. Indian J Crit Care Med, 2018, 22(2): 67-77.
63.	Park JJ, Seo YB, Lee J, et al. Colistin monotherapy versus colistin-based combination therapy for treatment of bacteremia in burn patients due to carbapenem-resistant gram negative bacteria. Burns, 2020, 46(8): 1848-1856.
64.	Wang SH, Yang KY, Sheu CC, et al. Efficacies of colistin-carbapenem versus colistin-tigecycline in critically ill patients with CR-GNB-associated pneumonia: a multicenter observational study. Antibiotics (Basel), 2021, 10(9): 1081.
65.	Vo TPM, Dinh TC, Phan HV, et al. Ventilator-associated pneumonia caused by multidrug-resistant gram-negative bacteria in Vietnam: antibiotic resistance, treatment outcomes, and colistin-associated adverse effects. Healthcare (Basel), 2022, 10(9): 1765.
66.	Ghafur A, Devarajan V, Raja T, et al. Monotherapy versus combination therapy against nonbacteremic carbapenem-resistant gram-negative infections: a retrospective observational study. Indian J Crit Care Med, 2017, 21(12): 825-829.
67.	Keski N AS, Seyman D, Önder KD, et al. Investigation of effect of the colistin loading dosage on the clinical, microbiological, and laboratory results in Acinetobacter baumannii ventilator-associated pneumonia /pneumonia. Int J Clin Pract, 2022, 2022: 5437850.
68.	Chang K, Wang H, Zhao J, et al. Polymyxin B/tigecycline combination vs. polymyxin b or tigecycline alone for the treatment of hospital-acquired pneumonia caused by carbapenem-resistant enterobacteriaceae or carbapenem-resistant Acinetobacter baumannii. Front Med (Lausanne), 2022, 9: 772372.
69.	Zhang X, Qi S, Duan X, et al. Clinical outcomes and safety of polymyxin B in the treatment of carbapenem-resistant Gram-negative bacterial infections: a real-world multicenter study. J Transl Med, 2021, 19(1): 431.
70.	Sheng WH, Wang JT, Li SY, et al. Comparative in vitro antimicrobial susceptibilities and synergistic activities of antimicrobial combinations against carbapenem-resistant Acinetobacter species: Acinetobacter baumannii versus Acinetobacter genospecies 3 and 13TU. Diagn Microbiol Infect Dis, 2011, 70(3): 380-6.
71.	Oliveira MS, Prado GV, Costa SF, et al. Ampicillin/sulbactam compared with polymyxins for the treatment of infections caused by carbapenem-resistant Acinetobacter spp. J Antimicrob Chemother, 2008, 61(6): 1369-1375.
72.	Ni W, Han Y, Zhao J, et al. Tigecycline treatment experience against multidrug-resistant Acinetobacter baumannii infections: a systematic review and meta-analysis. Int J Antimicrob Agents, 2016, 47(2): 107-16.
73.	Kengkla K, Kongpakwattana K, Saokaew S, et al. Comparative efficacy and safety of treatment options for MDR and XDR Acinetobacter baumannii infections: a systematic review and network meta-analysis. J Antimicrob Chemother, 2018, 73(1): 22-32.
74.	Liu J, Shu Y, Zhu F, et al. Comparative efficacy and safety of combination therapy with high-dose sulbactam or colistin with additional antibacterial agents for multiple drug-resistant and extensively drug-resistant Acinetobacter baumannii infections: a systematic review and network meta-analysis. J Glob Antimicrob Resist, 2021, 24: 136-147.
75.	周华, 周建英, 俞云松. 多重耐药革兰阴性杆菌感染诊治专家共识解读. 中华内科杂志, 2014, 53(12): 984-987.
76.	王明贵, 管向东, 何礼贤, 等. 广泛耐药革兰阴性菌感染的实验诊断、抗菌治疗及医院感染控制: 中国专家共识. 中国感染与化疗杂志, 2017, 17(1): 82-92.
77.	Lin MH, Shen YC, Cheng HY, et al. Comparative efficacy and safety of non-polymyxin antibiotics against nosocomial pneumonia, complicated intra-abdominal infection, or complicated urinary tract infection: a network meta-analysis of randomised clinical trials. J Glob Antimicrob Resist, 2023, 34: 46-58.
78.	Han R, Teng M, Zhang Y, et al. Choosing optimal antibiotics for the treatment of patients infected with enterobacteriaceae: a network meta-analysis and cost-effectiveness analysis. Front Pharmacol, 2021, 12: 656790.

1. Zheng JY, Huang SS, Huang SH, et al. Colistin for pneumonia involving multidrug-resistant Acinetobacter calcoaceticus-Acinetobacter baumannii complex. J Microbiol Immunol Infect, 2020, 53(6): 854-865.
2. Lodise TP, Bassetti M, Ferrer R, et al. All-cause mortality rates in adults with carbapenem-resistant Gram-negative bacterial infections: a comprehensive review of pathogen-focused, prospective, randomized, interventional clinical studies. Expert Rev Anti Infect Ther, 2022, 20(5): 707-719.
3. Bassetti M, Echols R, Matsunaga Y, et al. Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial. Lancet Infect Dis, 2021, 21(2): 226-240.
4. Kengkla K, Kongpakwattana K, Saokaew S, et al. Comparative efficacy and safety of treatment options for MDR and XDR Acinetobacter baumannii infections: a systematic review and network meta-analysis. J Antimicrob Chemother, 2018, 73(1): 22-32.
5. Hutton B, Salanti G, Caldwell DM, et al. The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann Intern Med, 2015, 162(11): 777-784.
6. Paul M, Daikos GL, Durante-Mangoni E, et al. Colistin alone versus colistin plus meropenem for treatment of severe infections caused by carbapenem-resistant Gram-negative bacteria: an open-label, randomised controlled trial. Lancet Infect Dis, 2018, 18(4): 391-400.
7. Khalili H, Shojaei L, Mohammadi M, et al. Meropenem/colistin versus meropenem/ampicillin-sulbactam in the treatment of carbapenem-resistant pneumonia. J Comp Eff Res, 2018, 7(9): 901-911.
8. Wunderink RG, Matsunaga Y, Ariyasu M, et al. Cefiderocol versus high-dose, extended-infusion meropenem for the treatment of Gram-negative nosocomial pneumonia (APEKS-NP): a randomised, double-blind, phase 3, non-inferiority trial. Lancet Infect Dis, 2021, 21(2): 213-225.
9. Sirijatuphat R, Thamlikitkul V. Preliminary study of colistin versus colistin plus fosfomycin for treatment of carbapenem-resistant Acinetobacter baumannii infections. Antimicrob Agents Chemother, 2014, 58(9): 5598-5601.
10. Durante-Mangoni E, Signoriello G, Andini R, et al. Colistin and rifampicin compared with colistin alone for the treatment of serious infections due to extensively drug-resistant Acinetobacter baumannii: a multicenter, randomized clinical trial. Clin Infect Dis, 2013, 57(3): 349-358.
11. Aydemir H, Akduman D, Piskin N, et al. Colistin vs. the combination of colistin and rifampicin for the treatment of carbapenem-resistant Acinetobacter baumannii ventilator-associated pneumonia. Epidemiol Infect, 2013, 141(6): 1214-1222.
12. Cisneros JM, Rosso-Fernández CM, Roca-Oporto C, et al. Colistin versus meropenem in the empirical treatment of ventilator-associated pneumonia (Magic Bullet study): an investigator-driven, open-label, randomized, noninferiority controlled trial. Crit Care, 2019, 23(1): 383.
13. Amat T, Gutiérrez-Pizarraya A, Machuca I, et al. The combined use of tigecycline with high-dose colistin might not be associated with higher survival in critically ill patients with bacteraemia due to carbapenem-resistant Acinetobacter baumannii. Clin Microbiol Infect, 2018, 24(6): 630-634.
14. Batirel A, Balkan II, Karabay O, et al. Comparison of colistin-carbapenem, colistin-sulbactam, and colistin plus other antibacterial agents for the treatment of extremely drug-resistant Acinetobacter baumannii bloodstream infections. Eur J Clin Microbiol Infect Dis, 2014, 33(8): 1311-1322.
15. Katip W, Uitrakul S, Oberdorfer P. The effectiveness and nephrotoxicity of loading dose colistin combined with or without meropenem for the treatment of carbapenem-resistant A. baumannii. Int J Infect Dis, 2020, 97: 391-395.
16. Falagas ME, Rafailidis PI, Ioannidou E, et al. Colistin therapy for microbiologically documented multidrug-resistant Gram-negative bacterial infections: a retrospective cohort study of 258 patients. Int J Antimicrob Agents, 2010, 35(2): 194-199.
17. Yilmaz GR, Guven T, Guner R, et al. Colistin alone or combined with sulbactam or carbapenem against A. baumannii in ventilator-associated pneumonia. J Infect Dev Ctries, 2015, 9(5): 476-487.
18. Michalopoulos A, Fotakis D, Virtzili S, et al. Aerosolized colistin as adjunctive treatment of ventilator-associated pneumonia due to multidrug-resistant Gram-negative bacteria: a prospective study. Respir Med, 2008, 102(3): 407-412.
19. Abdelsalam MFA, Abdalla MS, El-Abhar HSE. Prospective, comparative clinical study between high-dose colistin monotherapy and colistin-meropenem combination therapy for treatment of hospital-acquired pneumonia and ventilator-associated pneumonia caused by multidrug-resistant Klebsiella pneumoniae. J Glob Antimicrob Resist, 2018, 15: 127-135.
20. Paul M, Bishara J, Levcovich A, et al. Effectiveness and safety of colistin: prospective comparative cohort study. J Antimicrob Chemother, 2010, 65(5): 1019-1027.
21. Shields RK, Nguyen MH, Chen L, et al. Ceftazidime-avibactam is superior to other treatment regimens against carbapenem-resistant Klebsiella pneumoniae bacteremia. Antimicrob Agents Chemother, 2017, 61(8): e00883-817.
22. Rigatto MH, Vieira FJ, Antochevis LC, et al. Polymyxin B in combination with antimicrobials lacking in vitro activity versus polymyxin b in monotherapy in critically Ill patients with acinetobacter baumannii or pseudomonas aeruginosa infections. Antimicrob Agents Chemother, 2015, 59(10): 6575-6580.
23. Crusio R, Rao S, Changawala N, et al. Epidemiology and outcome of infections with carbapenem-resistant Gram-negative bacteria treated with polymyxin B-based combination therapy. Scand J Infect Dis, 2014, 46(1): 1-8.
24. López-Cortés LE, Cisneros JM, Fernández-Cuenca F, et al. Monotherapy versus combination therapy for sepsis due to multidrug-resistant Acinetobacter baumannii: analysis of a multicentre prospective cohort. J Antimicrob Chemother, 2014, 69(11): 3119-3126.
25. Falagas ME, Rafailidis PI, Kasiakou SK, et al. Effectiveness and nephrotoxicity of colistin monotherapy vs. colistin-meropenem combination therapy for multidrug-resistant Gram-negative bacterial infections. Clin Microbiol Infect, 2006, 12(12): 1227-1230.
26. Petrosillo N, Giannella M, Antonelli M, et al. Clinical experience of colistin-glycopeptide combination in critically ill patients infected with Gram-negative bacteria. Antimicrob Agents Chemother, 2014, 58(2): 851-858.
27. Katip W, Oberdorfer P. Clinical efficacy and nephrotoxicity of colistin alone versus colistin plus vancomycin in critically Ill patients infected with Carbapenem-resistant Acinetobacter baumannii: a propensity score-matched analysis. Pharmaceutics, 2021, 13(2): 162.
28. Park SY, Si HJ, Eom JS, et al. Survival of carbapenem-resistant Acinetobacter baumannii bacteremia: colistin monotherapy versus colistin plus meropenem. J Int Med Res, 2019, 47(12): 5977-5985.
29. Shi H, Lee JS, Park SY, et al. Colistin plus carbapenem versus colistin monotherapy in the treatment of Carbapenem-resistant Acinetobacter baumannii pneumonia. Infect Drug Resist, 2019, 12: 3925-3934.
30. Katip W, Uitrakul S, Oberdorfer P. A comparison of colistin versus colistin plus meropenem for the treatment of Carbapenem-resistant Acinetobacter baumannii in critically Ill patients: a propensity score-matched analysis. Antibiotics (Basel), 2020, 9(10): 647.
31. Seok H, Choi WS, Lee S, et al. What is the optimal antibiotic treatment strategy for carbapenem-resistant Acinetobacter baumannii (CRAB). A multicentre study in Korea. J Glob Antimicrob Resist, 2021, 24: 429-439.
32. Qureshi ZA, Paterson DL, Potoski BA, et al. Treatment outcome of bacteremia due to KPC-producing Klebsiella pneumoniae: superiority of combination antimicrobial regimens. Antimicrob Agents Chemother, 2012, 56(4): 2108-2113.
33. Simsek F, Gedik H, Yildirmak MT, et al. Colistin against colistin-only-susceptible Acinetobacter baumannii-related infections: monotherapy or combination therapy. Indian J Med Microbiol, 2012, 30(4): 448-452.
34. Lee CM, Lim HK, Liu CP, et al. Treatment of pan-drug resistant Acinetobacter baumannii. Scand J Infect Dis, 2005, 37(3): 195-199.
35. Chan JD, Graves JA, Dellit TH. Antimicrobial treatment and clinical outcomes of carbapenem-resistant Acinetobacter baumannii ventilator-associated pneumonia. J Intensive Care Med, 2010, 25(6): 343-348.
36. Tasbakan MS, Pullukcu H, Sipahi OR, et al. Is tigecyclin a good choice in the treatment of multidrug-resistant Acinetobacter baumannii pneumonia. J Chemother, 2011, 23(6): 345-349.
37. Garnacho-Montero J, Amaya-Villar R, Gutiérrez-Pizarraya A, et al. Clinical efficacy and safety of the combination of colistin plus vancomycin for the treatment of severe infections caused by carbapenem-resistant Acinetobacter baumannii. Chemotherapy, 2013, 59(3): 225-231.
38. Jean SS, Hsieh TC, Hsu CW, et al. Comparison of the clinical efficacy between tigecycline plus extended-infusion imipenem and sulbactam plus imipenem against ventilator-associated pneumonia with pneumonic extensively drug-resistant Acinetobacter baumannii bacteremia, and correlation of clinical efficacy with in vitro synergy tests. J Microbiol Immunol Infect, 2016, 49(6): 924-933.
39. Cheng A, Chuang YC, Sun HY, et al. Excess mortality associated with colistin-tigecycline compared with colistin-carbapenem combination therapy for extensively drug-resistant Acinetobacter baumannii bacteremia: a multicenter prospective observational study. Crit Care Med, 2015, 43(6): 1194-1204.
40. Khawcharoenporn T, Pruetpongpun N, Tiamsak P, et al. Colistin-based treatment for extensively drug-resistant Acinetobacter baumannii pneumonia. Int J Antimicrob Agents, 2014, 43(4): 378-382.
41. Kalin G, Alp E, Akin A, et al. Comparison of colistin and colistin/sulbactam for the treatment of multidrug resistant Acinetobacter baumannii ventilator-associated pneumonia. Infection, 2014, 42(1): 37-42.
42. 张银维, 周华, 蔡洪流, 等. 鲍曼不动杆菌血流感染临床特征和死亡危险因素分析. 中华内科杂志, 2016, 55(2): 121-126.
43. 贺黉裕, 吴雪飞, 居旻杰, 等. 多黏菌素B对脓毒症合并泛耐药革兰阴性菌感染患者的疗效. 中国临床医学, 2021, 28(2): 241-247.
44. 邱莹玉. 硫酸多粘菌素B与美罗培南联用对泛耐药鲍曼不动杆菌菌血症患者的临床疗效与安全性评价. 抗感染药学, 2019, 16(3): 427-429.
45. 徐玲. 硫酸多粘菌素B与美罗培南联用对泛耐药鲍曼不动杆菌菌血症患者的临床疗效与安全性评价. 抗感染药学, 2019, 16(10): 1743-1745.
46. 赵军喜. 美罗培南加左氧氟沙星静滴联合阿米卡星雾化吸入治疗肺部泛耐药铜绿假单胞菌感染. 航空航天医学杂志, 2013, 24(4): 474-475.
47. 汪卫立, 丁伟琪, 黄建东, 等. 美罗培南联合硫酸多粘菌素B对泛耐药鲍曼不动杆菌菌血症患者效果观察及对PCT和CRP影响. 全科医学临床与教育, 2020, 18(3): 212-214.
48. 王玺, 胡艳, 阙呈立, 等. 碳青霉烯类抗生素延长输注联合舒巴坦对广泛耐药鲍曼不动杆菌呼吸机相关性肺炎的疗效. 中华医学杂志, 2017, 97(38): 2996-3000.
49. 王龙梅, 高志凌, 尹硕淼, 等. 头孢哌酮/舒巴坦联合替加环素对耐碳青霉烯类鲍曼不动杆菌感染患者APACHEⅡ评分及炎症反应的影响. 现代生物医学进展, 2022, 22(19): 3776-3779.
50. 詹晓娟, 秦中辉. 替加环素联合头孢哌酮舒巴坦钠在耐碳青霉烯类耐药鲍曼不动杆菌肺炎患者抗感染中的疗效分析. 中国医学工程, 2022, 30(6): 75-78.
51. 李瑞霞. 替加环素与头孢哌酮-舒巴坦联用对耐碳青霉烯类鲍曼不动杆菌肺炎患者的疗效及其对炎症因子的影响. 抗感染药学, 2017, 14(7): 1372-1374.
52. 杨建辉, 孟园园. 替加环素联合注射用头孢哌酮舒巴坦钠治疗碳青霉烯类耐药鲍曼不动杆菌所致医院获得性肺炎患者的效果. 河南医学研究, 2021, 30(10): 1825-1827.
53. Zheng JY, Huang SS, Huang SH, et al. Colistin for pneumonia involving multidrug-resistant Acinetobacter calcoaceticus-Acinetobacter baumannii complex. J Microbiol Immunol Infect, 2020, 53(6): 854-865.
54. Guner R, Hasanoglu I, Keske S, et al. Outcomes in patients infected with carbapenem-resistant Acinetobacter baumannii and treated with tigecycline alone or in combination therapy. Infection, 2011, 39(6): 515-518.
55. Ku K, Pogue JM, Moshos J, et al. Retrospective evaluation of colistin versus tigecycline for the treatment of Acinetobacter baumannii and/or carbapenem-resistant Enterobacteriaceae infections. Am J Infect Control, 2012, 40(10): 983-987.
56. Tsioutis C, Kritsotakis EI, Karageorgos SA, et al. Clinical epidemiology, treatment and prognostic factors of extensively drug-resistant Acinetobacter baumannii ventilator-associated pneumonia in critically ill patients. Int J Antimicrob Agents, 2016, 48(5): 492-497.
57. Kofteridis DP, Andrianaki AM, Maraki S, et al. Treatment pattern, prognostic factors, and outcome in patients with infection due to pan-drug-resistant gram-negative bacteria. Eur J Clin Microbiol Infect Dis, 2020, 39(5): 965-970.
58. Ghafur A, Devarajan V, Raja T, et al. Monotherapy versus combination therapy against carbapenem-resistant Gram-negative bacteria: a retrospective observational study. Indian J Cancer, 2016, 53(4): 592-594.
59. Zaidi ST, Al Omran S, Al Aithan AS, et al. Efficacy and safety of low-dose colistin in the treatment for infections caused by multidrug-resistant gram-negative bacteria. J Clin Pharm Ther, 2014, 39(3): 272-276.
60. Wagenlehner FME, Cloutier DJ, Komirenko AS, et al. Once-daily plazomicin for complicated urinary tract infections. N Engl J Med, 2019, 380(8): 729-740.
61. Qu J, Feng C, Li H, et al. Antibiotic strategies and clinical outcomes for patients with carbapenem-resistant Gram-negative bacterial bloodstream infection. Int J Antimicrob Agents, 2021, 57(3): 106284.
62. Makris D, Petinaki E, Tsolaki V, et al. Colistin versus colistin combined with ampicillin-sulbactam for multiresistant Acinetobacter baumannii ventilator-associated pneumonia treatment: an open-label prospective study. Indian J Crit Care Med, 2018, 22(2): 67-77.
63. Park JJ, Seo YB, Lee J, et al. Colistin monotherapy versus colistin-based combination therapy for treatment of bacteremia in burn patients due to carbapenem-resistant gram negative bacteria. Burns, 2020, 46(8): 1848-1856.
64. Wang SH, Yang KY, Sheu CC, et al. Efficacies of colistin-carbapenem versus colistin-tigecycline in critically ill patients with CR-GNB-associated pneumonia: a multicenter observational study. Antibiotics (Basel), 2021, 10(9): 1081.
65. Vo TPM, Dinh TC, Phan HV, et al. Ventilator-associated pneumonia caused by multidrug-resistant gram-negative bacteria in Vietnam: antibiotic resistance, treatment outcomes, and colistin-associated adverse effects. Healthcare (Basel), 2022, 10(9): 1765.
66. Ghafur A, Devarajan V, Raja T, et al. Monotherapy versus combination therapy against nonbacteremic carbapenem-resistant gram-negative infections: a retrospective observational study. Indian J Crit Care Med, 2017, 21(12): 825-829.
67. Keski N AS, Seyman D, Önder KD, et al. Investigation of effect of the colistin loading dosage on the clinical, microbiological, and laboratory results in Acinetobacter baumannii ventilator-associated pneumonia /pneumonia. Int J Clin Pract, 2022, 2022: 5437850.
68. Chang K, Wang H, Zhao J, et al. Polymyxin B/tigecycline combination vs. polymyxin b or tigecycline alone for the treatment of hospital-acquired pneumonia caused by carbapenem-resistant enterobacteriaceae or carbapenem-resistant Acinetobacter baumannii. Front Med (Lausanne), 2022, 9: 772372.
69. Zhang X, Qi S, Duan X, et al. Clinical outcomes and safety of polymyxin B in the treatment of carbapenem-resistant Gram-negative bacterial infections: a real-world multicenter study. J Transl Med, 2021, 19(1): 431.
70. Sheng WH, Wang JT, Li SY, et al. Comparative in vitro antimicrobial susceptibilities and synergistic activities of antimicrobial combinations against carbapenem-resistant Acinetobacter species: Acinetobacter baumannii versus Acinetobacter genospecies 3 and 13TU. Diagn Microbiol Infect Dis, 2011, 70(3): 380-6.
71. Oliveira MS, Prado GV, Costa SF, et al. Ampicillin/sulbactam compared with polymyxins for the treatment of infections caused by carbapenem-resistant Acinetobacter spp. J Antimicrob Chemother, 2008, 61(6): 1369-1375.
72. Ni W, Han Y, Zhao J, et al. Tigecycline treatment experience against multidrug-resistant Acinetobacter baumannii infections: a systematic review and meta-analysis. Int J Antimicrob Agents, 2016, 47(2): 107-16.
73. Kengkla K, Kongpakwattana K, Saokaew S, et al. Comparative efficacy and safety of treatment options for MDR and XDR Acinetobacter baumannii infections: a systematic review and network meta-analysis. J Antimicrob Chemother, 2018, 73(1): 22-32.
74. Liu J, Shu Y, Zhu F, et al. Comparative efficacy and safety of combination therapy with high-dose sulbactam or colistin with additional antibacterial agents for multiple drug-resistant and extensively drug-resistant Acinetobacter baumannii infections: a systematic review and network meta-analysis. J Glob Antimicrob Resist, 2021, 24: 136-147.
75. 周华, 周建英, 俞云松. 多重耐药革兰阴性杆菌感染诊治专家共识解读. 中华内科杂志, 2014, 53(12): 984-987.
76. 王明贵, 管向东, 何礼贤, 等. 广泛耐药革兰阴性菌感染的实验诊断、抗菌治疗及医院感染控制: 中国专家共识. 中国感染与化疗杂志, 2017, 17(1): 82-92.
77. Lin MH, Shen YC, Cheng HY, et al. Comparative efficacy and safety of non-polymyxin antibiotics against nosocomial pneumonia, complicated intra-abdominal infection, or complicated urinary tract infection: a network meta-analysis of randomised clinical trials. J Glob Antimicrob Resist, 2023, 34: 46-58.
78. Han R, Teng M, Zhang Y, et al. Choosing optimal antibiotics for the treatment of patients infected with enterobacteriaceae: a network meta-analysis and cost-effectiveness analysis. Front Pharmacol, 2021, 12: 656790.

Chinese Journal of Evidence-Based Medicine

Latest ArticlesEfficiency and safety of 12 antimicrobial drug regimens against multidrug-resistant gram-negative bacterial infections: a network meta-analysis

Abstract Full text Figures/Tables Video References Cited by

Format

Content